Select Clinical Trial
Gastroesophageal Junction Cancer
GS-US-296-1080: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of GS-5745 Combined With mFOLFOX6 as First Line Treatment in Patients With Advanced Gastric or Gastroesophageal Junction Adenocarcinoma
- Men and women, ages 18 and older, diagnosed with cancer of the stomach or gastroesophageal junction. For more information, please contact the study coordinator at 910-715-2200.
Gilead GS US 296-2013/ GE Junction
- Study to Evaluate the Efficacy and Safety of GS-5745 Combined With Nivolumab Versus Nivolumab Alone in Subjects With Unresectable or Recurrent Gastric or Gastroesophageal Junction Adenocarcinoma
- Patient population 18 years and older; Histologically confirmed inoperable locally advanced or metastatic adenocarcinoma of the stomach or GEJ